Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F. Seymour, Andrew W. Roberts, Shuo Ma et al.|The Lancet Oncology|2017Cited by 327
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Simon J. Harrison, Jia Jia et al.|Blood|2017Cited by 271
Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b StudyShuo Ma, Andrew W. Roberts, Danielle M. Brander et al.|Blood|2015Cited by 50
Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)Andrew W. Roberts, John F. Seymour, Shuo Ma et al.|Blood|2014Cited by 44
ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.Shuo Ma, Andrew W. Roberts, John F. Seymour et al.|Journal of Clinical Oncology|2014Cited by 22